Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase III, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

被引：0
|
作者：
Blauvelt, A. [1 ]
Wollenberg, A. [2 ]
Pink, A. [3 ]
Peris, K. [4 ,5 ]
Armstrong, A. [6 ]
Spelman, L. [7 ,8 ]
Saeki, H. [9 ]
Lynde, C. [10 ,11 ]
Herranz, P. [12 ]
Barbarot, S. [13 ]
Simpson, E. [14 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Ludwig Maximilian Univ Munich, Dept Dermatol & Allergol, Munich, Germany
[3] Guys & St Thomas Hosp, St Johns Inst Dermatol, London, England
[4] Catholic Univ, Dermatol, Rome, Italy
[5] IRCCS, Fdn Policlin Univ A Gemelli, Rome, Italy
[6] Univ Southern Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA 90007 USA
[7] Verac Clin Res, Brisbane, Qld, Australia
[8] Prob Med Res, Woolloongabba, Qld, Australia
[9] Nippon Med Sch, Dept Dermatol, Tokyo, Japan
[10] Prob Med Res, Lynde Dermatol, Markham, ON, Canada
[11] Univ Toronto, Dept Med, Toronto, ON, Canada
[12] Hosp Univ La Paz, Dept Dermatol, Madrid, Spain
[13] Ctr Hosp Univ Nantes, Nantes, France
[14] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2021年 / 185卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
447
引用
收藏
页码：E110 / E111
页数：2
相关论文
共 50 条
  • [41] The effect of dupilumab on vaccine antibody responses in adults with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial
    Blauvelt, A.
    Simpson, E.
    Wu, R.
    Akinlade, B.
    Graham, N.
    Pirozzi, G.
    Evans, R.
    ALLERGY, 2016, 71 : 95 - 95
  • [42] Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study
    Cai, L.
    Gu, J.
    Zheng, J.
    Zheng, M.
    Wang, G.
    Xi, L. -Y.
    Hao, F.
    Liu, X. -M.
    Sun, Q. -N.
    Wang, Y.
    Lai, W.
    Fang, H.
    Tu, Y. -T.
    Sun, Q.
    Chen, J.
    Gao, X. -H.
    Gu, Y.
    Teixeira, H. D.
    Zhang, J. -Z.
    Okun, M. M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (01) : 89 - 95
  • [43] Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Open-Label Study
    Kestemont, Philippe
    Hilton, Said
    Andriopoulos, Bill
    Prygova, Inna
    Thompson, Catherine
    Volteau, Magali
    Ascher, Benjamin
    AESTHETIC SURGERY JOURNAL, 2022, 42 (03) : 301 - 313
  • [44] Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa study
    Bissonnette, Robert
    Abramovits, William
    Proulx, Etienne Saint-Cyr
    Lee, Patricia
    Guttman-Yassky, Emma
    Zovko, Elizabeta
    Sigmund, Ralf
    Willcox, Joanne
    Bieber, Thomas
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (03) : 549 - 557
  • [45] Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial
    Merola, Joseph F.
    Parish, Lawrence Charles
    Guenther, Lyn
    Lynde, Charles
    Lacour, Jean -Philippe
    Staubach, Petra
    Cheng, Sue
    Paris, Maria
    Picard, Hernan
    Deignan, Cynthia
    Jardon, Shauna
    Chen, Mindy
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (03) : 485 - 493
  • [46] Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study
    Saeki, H.
    Kabashima, K.
    Tokura, Y.
    Murata, Y.
    Shiraishi, A.
    Tamamura, R.
    Randazzo, B.
    Imanaka, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (02) : 419 - 427
  • [47] A phase 2b, randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of ANB032 in the treatment of moderate-to-severe atopic dermatitis
    Ehst, B.
    Silverberg, J.
    Lizzul, P.
    Luu, K.
    Papacharalambous, J.
    Raina, P.
    Randazzo, B.
    Sibley, C.
    Guttman-Yassky, E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S347 - S347
  • [48] Rocatinlimab significantly improves clinical responses in patients with moderate-to-severe atopic dermatitis by week 2 in a randomized double-blind placebo-controlled phase 2b study
    Guttman-Yassky, Emma
    Esfandiari, Ehsanollah
    Mano, Hirotaka
    Arai, Takahiro
    Kabashima, Kenji
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [49] A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease
    Targan, Stephan R.
    Feagan, Brian
    Vermeire, Severine
    Panaccione, Remo
    Melmed, Gil Y.
    Landers, Carol
    Li, Dalin
    Russell, Chris
    Newmark, Richard
    Zhang, Nan
    Chon, Yun
    Hsu, Yi-Hsiang
    Lin, Shao-Lee
    Klekotka, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (11): : 1599 - 1607
  • [50] Impact of targeting interleukin-13 on Staphylococcus aureus colonization: results from a phase III, randomized, double-blind, placebo-controlled trial with tralokinumab in adult patients with atopic dermatitis
    Bieber, T.
    Beck, L. A.
    Pink, A.
    Saeki, H.
    Eichenfield, L.
    Werfel, T.
    Rosholm, A.
    Roepke, M.
    Paller, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E112 - E112
12345